None (i.e. Healthy Volunteers) Clinical Trial
Official title:
Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males
Verified date | October 2021 |
Source | University of Ottawa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 7 days (+/- 1 day) throughout a 20 - 28 day period. After each dose escalation study participants will be asked to come to the clinic to conduct the necessary tests - these will include tyramine pressor tests as well as blood draws. The results of this study will allow the investigators to determine the dose(s) of levomilnacipran at which reuptake inhibition of norepinephrine and serotonin (chemicals utilized by nerve cells to transmit information to other cells) is achieved.
Status | Active, not recruiting |
Enrollment | 36 |
Est. completion date | May 1, 2022 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Male participants between 18 and 40 years-old - Written informed consent signed by the participant Exclusion Criteria: - Lifetime personal history of diagnosis of major depressive disorder according to the DSM-V (American Psychiatric Association, 2013) using the Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition (SCID-5-RV for DSM-V; First et al., 2015) - A history of suicidal ideation and behaviour, including self-harm and/or harm to others. - A history of substance abuse and/or dependence. - A positive drug screen for illicit drugs - Substantial alcohol use - Current use of Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue) - Current use of serotonin-precursors (such as L-tryptophan, oxitriptan) - Current use of serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort) - Concomitant use of NSAIDS, ASA, and other anticoagulants. - Current use of Thioridazine - Current use of CYP1A2 Inhibitors - Current use of Triptans (5HT1 Agonists) - Blood pressure greater than 140/90 and/or a pulse rate greater than 90 bpm - Recent history of myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease. - Evidence of significant physical illness contraindicating the use of levomilnacipran and duloxetine found on the physical exam or in the laboratory data obtained during the first week of the study - Current use of medication that may affect voiding (ie- anticholinergics) - History of obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders. - History of Stevens-Johnson Syndrome and Erythema multiforme. - Diabetes Type I and II - Fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency. - Hepatic Impairment - Uncontrolled narrow-angle glaucoma - Severe renal impairment - History of seizure disorder - Anatomically narrow ocular angles. - Osteoporosis or major risk for bone fractures. |
Country | Name | City | State |
---|---|---|---|
Canada | Institute of Mental Health Research, Royal Ottawa Mental Health Centre | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Ottawa | Allergan |
Canada,
Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat. 2015 Jan 9;11:125-35. doi: 10.2147/NDT.S54710. eCollection 2015. Review. — View Citation
Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O'Connor JA, Depoortère R. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013 Jul;70:338-47. doi: 10.1016/j.neuropharm.2013.02.024. Epub 2013 Mar 13. — View Citation
Blier P, Saint-André E, Hébert C, de Montigny C, Lavoie N, Debonnel G. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007 Feb;10(1):41-50. Epub 2006 May 11. — View Citation
Blier, P., Aldosary, F., Tremblay, P., & Hébert, C. (2010). Inhibition of norepinephrine and serotonin reuptake by venlafaxine, paroxetine and atomoxetine in depressed patients. Int J Neuropsychopharmacol 13(Suppl 1):143S.
Debonnel G, Saint-André E, Hébert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007 Feb;10(1):51-61. Epub 2006 May 11. — View Citation
First, M.B., Williams, J.B.W., Karg, R.S., & Spitzer, R.L. (2015). Structured clinical interview for DSM-5-research version. Arlington: American Psychiatric Association.
Gobbi G, Slater S, Boucher N, Debonnel G, Blier P. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol. 2003 Jun;23(3):233-9. — View Citation
Turcotte JE, Debonnel G, de Montigny C, Hébert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21. — View Citation
Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary End Point | The degree of norepinephrine reuptake in response to the increasing levels of the study medication will be assessed and compared between three treatment groups. | 24 months | |
Secondary | Secondary End Points | The degree of serotonin reuptake in response to the increasing levels of the study medication will be assessed and compared between three treatment groups. | 24 months |